The fixed-ratio combination of insulin glargine plus lixisenatide (iGlarLixi) improved beta-cell glucose sensitivity by 35% while sparing endogenous insulin release over 26 weeks in people with type 2 diabetes.
35% increase in β-cell glucose sensitivityiGlarLixi improved beta cells' ability to sense and respond to blood sugar by 35% compared to GLP-1RA alone, while simultaneously reducing the overall insulin production burden on the pancreas.
What the researchers found
After 26 weeks, iGlarLixi produced a 35% median increase in beta-cell glucose sensitivity compared to GLP-1RA alone (p=0.0032). HbA1c decreased significantly more with iGlarLixi than with GLP-1RA alone (p<0.0001).
Notably, iGlarLixi reduced both fasting and stimulated insulin secretion (both p<0.0001 vs. GLP-1RA), indicating that the beta cells were being spared from overproduction while functioning more efficiently. The incremental meal tolerance test glucose area also showed a larger reduction with iGlarLixi (p<0.0001). Body weight increased modestly in the iGlarLixi group (+1.7 kg, p<0.0001). In the GLP-1RA-only group, despite weight loss and HbA1c improvement, no beta-cell function parameters changed significantly.
Why it matters
Beta-cell dysfunction is the core defect driving type 2 diabetes progression. Finding that iGlarLixi not only improves blood sugar control but actually improves beta-cell function and spares insulin production suggests it may help preserve beta-cell health over time. This is a shift from simply treating high blood sugar to potentially modifying the underlying disease process.
How the study worked
Post-hoc analysis of the LixiLan-G randomized trial (NCT02787551) including 351 participants with type 2 diabetes on metformin. Participants were randomized to iGlarLixi (n=189) or continued daily/weekly GLP-1RA (n=162) for 26 weeks. Beta-cell function was assessed using 2-hour meal tolerance tests with timed glucose and C-peptide measurements at baseline and week 26, analyzed with mathematical modeling to derive insulin secretion and glucose sensitivity parameters.
What this study cannot tell us
This was a post-hoc analysis of a clinical trial, not designed primarily to assess beta-cell function. The 26-week duration may not capture longer-term effects on beta-cell health. The modest weight gain with iGlarLixi is a trade-off compared to the weight loss seen with GLP-1RA alone. Only participants on metformin were included, limiting generalizability. Mathematical modeling of beta-cell function is an indirect assessment.
How to read the evidence
This is a post-hoc analysis of a randomized controlled trial with a substantial sample size (351 participants). The RCT design and detailed beta-cell function assessment provide reasonably strong evidence, though the post-hoc nature means the findings should be confirmed in prospective studies.
When this study was published
Published in 2022 based on the LixiLan-G trial, this study provides mechanistic insight into a combination therapy that is currently available for clinical use.
The bigger picture
Fixed-ratio combinations of basal insulin and GLP-1 receptor agonists represent a practical advance in diabetes management, simplifying treatment by combining two drugs in one injection. This study adds a mechanistic dimension — showing that the combination doesn't just lower blood sugar but actually improves how beta cells function. This finding supports the growing evidence that GLP-1-based therapies may have disease-modifying potential in type 2 diabetes.
Questions still open
- Does the improvement in beta-cell function with iGlarLixi persist or increase beyond 26 weeks?
- Could iGlarLixi slow the progressive beta-cell decline that characterizes type 2 diabetes?
- How does iGlarLixi's beta-cell effect compare to newer combinations like insulin plus tirzepatide?
Common questions
What is iGlarLixi and how does it work?
Why is improving beta-cell function important in diabetes?
Read the original research
Fixed-ratio combination of insulin glargine plus lixisenatide (iGlarLixi) improves ß-cell function in people with type 2 diabetes.
Diabetes, obesity & metabolism, 24(6), 1159-1165
Citation
Ferrannini, Ele; Niemoeller, Elisabeth; Dex, Terry; Servera, Soraly; Mari, Andrea. (2022). Fixed-ratio combination of insulin glargine plus lixisenatide (iGlarLixi) improves ß-cell function in people with type 2 diabetes.. Diabetes, obesity & metabolism, 24(6), 1159-1165. https://doi.org/10.1111/dom.14688